Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells (2006)
- Authors:
- USP affiliated authors: CASTRO, FABÍOLA ATTIÉ DE - FCFRP ; MENDES, JOAO GUSTAVO PESSINI AMARANTE - ICB
- Unidades: FCFRP; ICB
- Subjects: QUIMIOTERÁPICOS; APOPTOSE; ONCOPROTEÍNAS
- Language: Inglês
- Imprenta:
- Publisher place: Angra dos Reis
- Date published: 2006
- Source:
- Título do periódico: Program and Abstract Book
- Conference titles: International Cell Death Symposium on
-
ABNT
FURLAN, Renata Lígia A. et al. Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells. 2006, Anais.. Angra dos Reis: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, 2006. . Acesso em: 24 abr. 2024. -
APA
Furlan, R. L. A., Ulbrich, A., Brumatti, G., Castro, F. A. de, Garrido, L. M., Padilla, G., & Amarante-Mendes, J. G. P. (2006). Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells. In Program and Abstract Book. Angra dos Reis: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. -
NLM
Furlan RLA, Ulbrich A, Brumatti G, Castro FA de, Garrido LM, Padilla G, Amarante-Mendes JGP. Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells. Program and Abstract Book. 2006 ;[citado 2024 abr. 24 ] -
Vancouver
Furlan RLA, Ulbrich A, Brumatti G, Castro FA de, Garrido LM, Padilla G, Amarante-Mendes JGP. Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells. Program and Abstract Book. 2006 ;[citado 2024 abr. 24 ] - Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide
- Development and characterization of murine models of T lymphoma to investigate the impact of oncogene expression
- T lymphoma murine models to study the impact of ectopic expression of anti-apoptotic oncogenes
- BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia
- Study of pro and anti-apoptotic genes to understand the resistance of apoptosis mediated by Bcr-Abl
- Indoleamine 2,3-dioxygenase expression in chronic myelogenous leukemia patients: association with disease progression
- Apoptotic genes expression in head and neck squamous cell carcinoma (HNSCC) patients
- Expression of pro-apoptotic bid and bik genes is decreased in chronic myeloid leukemia and low levels of bik MRNA are associated with lack of response to imatinib treatment
- BCR–ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
- Down regulation of Hematopoietic SH2 domain containing (HSH2D) in the progression of the chronic myelogenous leukemia
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
